VRTX rises 9.2% in three months but trails its industry as mixed new-drug sales and tightened 2025 guidance cloud near-term momentum.
Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities across its pipeline. JOURNAVX drives revenue with strong acute pain demand and is advancing into diabetic peripheral neuropathy (DPN) with two phase 3 studies enrolling through 2026. VRTX's BAFF/APRIL inhibitor povetacicept offers a 'pipeline in a pill' approach, targeting IgA Nephropathy and Primary Membranous Neuropathy, with key catalysts ahead and possible expansion opportunities.
VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.
| Software Industry | Information Technology Sector | Christopher David Young CEO | NASDAQ (NMS) Exchange | 92538J106 CUSIP |
| US Country | 1,900 Employees | - Last Dividend | - Last Split | 29 Jul 2020 IPO Date |
Vertex, Inc., established in 1978 and based in King of Prussia, Pennsylvania, operates internationally, offering cutting-edge tax technology solutions tailored for the retail trade, wholesale trade, and manufacturing industries. The company specializes in helping enterprises navigate the complex landscape of tax determination, compliance, reporting, and data management through a suite of products and services delivered both as traditional software licenses and modern Software as a Service (SaaS) subscriptions. With a focus on innovation, Vertex, Inc. leverages its extensive experience and industry-specific insights to provide comprehensive tax technology solutions designed to meet the evolving needs of its global clientele.